Latest news and press releases about Lantern Pharma Inc. (LTRN): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer.
Price
| Price | $1.93 |
| Market Cap | $25M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -7.45 |
| EV / EBITDA | -0.90 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -456.35% |
| Return on Invested Capital | -358.04% |
| Return on Assets | -216.84% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ANVS · ATNM · BCAB · CALC · ELUT · LVTX · MAIA
Explore sector: Healthcare · Biotechnology
More sections of LTRN: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks